Lake Street Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $10

Benzinga Newsdesk www.benzinga.com Neutral 55.5%

Neg 0% Neu 55.5% Pos 0%

Lake Street analyst Thomas Flaten initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a Buy rating and announces Price Target of $10.